Ovid Therapeutics Inc.

NASDAQ: OVID · Real-Time Price · USD
0.96
0.12 (14.24%)
At close: Aug 15, 2025, 3:59 PM
0.97
0.54%
After-hours: Aug 15, 2025, 07:58 PM EDT

Ovid Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
6.27M 130K 76K 173K 169K 148K 141.56K 108.97K 75K 66K 46.28K 11.1K n/a 1.45M -416.35M n/a n/a 208.38M
Cost of Revenue
99K n/a n/a 169K 148K 136K 401.39K 402.46K 394.77K 397.96K 439.95K 415.36K 440.97K n/a 56.87K 52K 53K n/a
Gross Profit
6.17M 130K 76K 173K 169K 148K 141.56K -293.49K 75M -332K -394K -404K -441K 1.45M -416.41M -52K -53K 208.38M
Operating Income
-5.07M -12.55M -10.72M -13.23M -20.52M -17.42M -18.19M -12.03M -14.17M -14.89M -12.17M -12.8M -14.3M -16.27M -26.35M -11.68M -14.31M 176.56M
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-4.68M -10.23M -9.25M -14.01M 8.52M -11.69M -15.32M -11.25M -12.41M -13.36M -11.51M -11.97M -14.59M -16.06M -26.35M -11.68M -14.31M 176.51M
Net Income
-4.68M -10.23M -9.25M -14.01M 8.52M -11.69M -15.32M -11.25M -12.41M -13.36M -11.46M -11.13M -14.59M -16.11M -26M -11.38M -15.79M 176.01M
Selling & General & Admin
4.88M 6.02M 4.87M 5.54M 8.1M 7.17M 7.69M 6.8M 8.25M 8.34M 6.67M 7.63M 8.26M 9.88M 8.26M 6.76M 6.63M 15.58M
Research & Development
6.46M 6.66M 5.92M 7.86M 12.58M 10.4M 10.64M 5.33M 5.89M 6.62M 5.41M 5.18M 6.05M 7.83M 18.09M 4.92M 7.68M 16.25M
Other Expenses
n/a n/a 1K n/a n/a n/a -957 n/a 1M n/a -700K -295 617.00 203.00 1.1K 2.66K -2.52K -49.73K
Operating Expenses
11.35M 12.68M 10.8M 13.4M 20.69M 17.57M 18.33M 12.14M 14.25M 14.96M 12.22M 12.4M 13.86M 17.71M 26.35M 11.68M 14.31M 31.82M
Interest Expense
n/a n/a n/a n/a n/a n/a 1.54B n/a n/a n/a n/a n/a 284.13K n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
11.35M 12.68M 10.8M 13.4M 20.69M 17.57M 18.33M 12.14M 14.25M 14.96M 12.22M 12.81M 14.3M 17.71M 26.35M 11.68M 14.31M 31.82M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -50K -836K n/a 50K -350K -295K 1.47M 500.28K
Shares Outstanding (Basic)
1.25M 71.05M 71.01M 70.98M 70.92M 70.72M 70.69M 70.62M 70.53M 70.3M 70.47M 70.4M 69.47M 70.03M 67.51M 66.97M 67.82M 66.09M
Shares Outstanding (Diluted)
71.11M 71.05M 71.01M 70.98M 71.2M 70.72M 70.69M 70.62M 70.53M 70.49M 70.47M 70.43M 70.39M 70.35M 68.16M 67.93M 67.82M 66.58M
EPS (Basic)
-0.07 -0.14 -0.13 -0.2 0.12 -0.17 -0.22 -0.16 -0.18 -0.19 -0.16 -0.16 -0.21 -0.23 -0.38 -0.17 -0.23 2.55
EPS (Diluted)
-0.07 -0.14 -0.13 -0.2 0.12 -0.17 -0.22 -0.16 -0.18 -0.19 -0.16 -0.16 -0.21 -0.23 -0.38 -0.17 -0.23 2.53
EBITDA
-5.07M -12.41M -10.76M -13.06M -20.37M -17.28M -14.92M -11.88M -14.17M -14.49M -11.73M -12.39M -14.15M -16.19M -26.3M -11.63M -14.26M 176.63M
EBIT
-4.68M -12.55M -10.92M -13.23M -20.52M -17.42M -15.32M -12.03M -13.17M -14.89M -12.17M -12.8M -14.3M -16.27M -26.35M -11.68M -14.31M 176.56M
Depreciation & Amortization
99K 141K 160K 169K 148K 136K 401.39K 146K -116K 398K 439.95K 415.36K 98.3K 73.81K 56.87K 52K 53K 74.73K